Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

  • Home
  • 2018
  • November
  • 15
  • Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

Original Source

On November 15, 2018

Post navigation

Previous PostNorwegian Cruise Line’s Record-Breaking Norwegian Bliss Arriving to Miami for Winter Season
Next PostBristol-Myers Squibb to Take Part in Evercore ISI HealthCONx Conference

Related Post

August 12, 2022
  • Business News

Modification to the Methodology of the S&P ESG Leaders Indices

August 12, 2022
  • Business News

Modification to the Methodology of the S&P Carbon Control Index Series

August 12, 2022
  • Business News

MACOM Technology Solutions Holdings Set to Join S&P MidCap 400

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219